Agonist actions of "β-blockers" provide evidence for two agonist activation sites or conformations of the human β1-adrenoceptor

Molecular Pharmacology

Volumn 63, Issue 6, 2003, Pages 1312-1321

  Baker, Jillian G ^a   Hall, Ian P ^a   Hill, Stephen J ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ACEBUTOLOL; ALPRENOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARVEDILOL; CATECHOLAMINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; LABETALOL; PINDOLOL; PROPRANOLOL;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; GENETIC TRANSCRIPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION;

ADRENERGIC BETA-ANTAGONISTS; ALKALINE PHOSPHATASE; ANIMALS; CARBAZOLES; CHO CELLS; CRICETINAE; CYCLIC AMP; GENE EXPRESSION; GENES, REPORTER; HUMANS; LUCIFERASES; PROPANOLAMINES; PROTEIN CONFORMATION; RECEPTORS, ADRENERGIC, BETA-1; TRITIUM;

EID: 0037764686     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.6.1312     Document Type: Article

References (39)

1. 2-adrenoceptor. Br J Pharmacol 137:400-408.
2. BEST (Beta-Blocker Evaluation of Survival Trial Investigators) (2001) A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659-1667.
3. CIBIS-II Investigators and Committees (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 353:9-13.
4. Cohen ML, Bloomquist W, Ito M, and Lowell BB (2000) Beta3 receptors mediate relaxation in stomach fundus whereas a fourth beta receptor mediates tachycardia in atria from transgenic beta3 receptor knockout mice. Recept Channels 7:17-23.
5. Cullen BR and Malim MH (1992) Secreted placental alkaline phosphatase as a eukaryotic reporter gene. Methods Enzymol 216:362-368.
6. Donaldson J, Brown AM, and Hill SJ (1988) Influence of rolipram on the cyclic-3′,5′-adenosine monophosphate response to histamine and adenosine in slices of guinea-pig cerebral cortex. Biochem Pharmacol 37:715-723.
7. Fraser IDC, Cong M, Kim J, Rollins EN, Daaka Y, Lefkowitz RJ, and Scott JD (2000) Assembly of an A kinase-anchoring protein-β2-adrenergic receptor complex facilitates receptor phosphorylation and signalling. Curr Biol 10:409-412.
8. 3H-CGP-12177 to cardiac tissue slices: characterization and ontogenetic studies in dogs. Can J Physiol Pharmacol 65: 928-1933.
9. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, and Hlatky MA (1999) Meta-analysis of trials comparing beta-blockers, calcium antagonists and nitrates for stable angina. J Am Med Assoc 281:1927-1936.
10. 2-adrenoceptors. Br J Pharmacol 131: 124-130.
11. Kaumann AJ (2000) Gs protein coupled receptors in human heart., in The Pharmacology of Functional, Biochemical and Recombinant Receptor Systems (Kenakin T, Angus JA eds) Handbook of Experimental Pharmacology, vol 148, pp 73-116, Springer, New York.
12. Kaumann AJ, Engelhardt S, Hein L, Molenaar P, and Lohse M (2001) Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology. Naunyn Schmiedeberg's Arch Pharmacol 363:87-93.
13. Kaumann AJ, Preitner F, Sarsero D, Molenaar P, Revelli JP, and Giacobino JP (1998) (-)-CGP 12177 causes cardiostimulation and binds to cardiac putative β4-adrenoceptors in both wild-type and β3-adrenoceptor knockout mice. Mol Pharmacol 53:670-675.
14. Kobilka B (1992) Adrenergic receptors as models for G protein-coupled receptors. Annu Rev Neurosci 15:87-114.
15. 1 receptor. J Pharmacol Exp Ther 281:761-768.
16. Konkar AA, Zhai Y, and Granneman JG (2000b) β1-adrenergic receptors mediate β3-adrenergic-independent effects of CGP 12177 in brown adipose tissue. Mol Pharmacol 57:252-258.
17. 1-adrenergic recepters receptors. J Pharmacol Exp Ther 294:923-932.
18. Lattion AL, Abuin L, Nenniger-Tosato M, and Cotecchia S (1999) Constitutively active mutants of the β1-adrenergic receptor. FEBS Lett 457:302-306.
19. 3H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol Pharmacol 58:194-207.
20. Lazareno S and Roberts FF (1987) Measuring muscarinic antagonist potency using phosphoinositide breakdown in rat cortex slices (Abstract). Br J Pharmacol 92:677P.
21. 2A-adrenoceptor: allosteric modulation by amilorides. Mol Pharmacol 58:1091-1099.
22. 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol 135:451-461.
23. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with folin phenol reagent. J Biol Chem 193:265-267.
24. Maack C, Cremers B, Flesch M, Hoper A, Sudkamp M, and Bohm M (2000) Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol 130:1131-1139.
25. McDonnell J, Latif ML, Rees ES, Bevan NJ, and Hill SJ (1998) Influence of receptor number on the stimulation by salmeterol of gene transcription in CHO-K1 cells transfected with the human β2-adrenoceptor. Br J Pharmacol 125:717-726.
26. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MER-IT-HF). Lancet 353:2001-2007.
27. Morgan TO, Anderson AIE, and MacInnis RJ (2001) ACE inhibitors, beta-blockers, calcium blockers and diuretics for the control of systolic hypertension. Am J Hypertension 14:241-247.
28. Mudumbri RV, Montamat SC, Bruns RF, and Vestal RE (1993) Cardiac functional-responses to adenosine by PD-81723, an allosteric enhancer of the adenosine-A1-receptor. Am J Physiol 264:H1017-H1022.
29. Nicholas G, Oakley C, Pouleur H, Rousseau MF, Ryden LE, and Wellens H (1990) Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group [published erratum appears in Lancet 336:698, 1990]. Lancet 336:1-6.
30. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, et al. (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658.
31. Pak MD and Fishman PH (1996) Anomalous behaviour of CGP 12177A on beta 1-adrenergic receptors. J Recept Signal Transduct Res 16:1-23.
32. Port JD and Bristow MR (2001) β-Adrenergic receptors, transgenic mice, and pharmacological model systems. Mol Pharmacol 60:629-631.
33. Salahpour A, Angers S, and Bouvier M (2000) Functional significance of oligomerization of G-protein-coupled receptors. Trends Endocrinol Metab 11:163-168.
34. Seifert R, Wenzel-Seifert K, Gether U, and Kolbilka BK (2001) Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther 297:1218-1226.
35. 1 muscarinic receptor. Mol Pharmacol 61:1297-1302.
36. Swangkoon S, Miyamoto M, Nakayama T, and Hamlin RL (2000) Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. Am J Vet Res 61:57-60.
37. Tendera M and Ochala A (2001) Overview of the results of recent beta blocker trials. Curr Opin Cardiol 16:180-185.
38. Wehling M (2002) Comparing beta-blockers and their relevance in the pharmacology of cardiovascular diseases. Arzneim-Forsch/Drug Res 52:73-80.
39. Wright JM (2000) Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: beta blockers. Can Med Assoc J 163:188-192.